The global alliance for pediatric pharmacology: the future is here and now.
The vast majority of drugs prescribed for children have not been approved by regulatory agencies for the pediatric age group and, in many cases, have not been studied appropriately. In July 2008, at a meeting of pediatric pharmacologists from over 30 countries and 5 continents in Toronto, ON, Canada, it became apparent that numerous pediatric drug studies are being conducted, often duplicating studies done elsewhere. This is also true for pharmacokinetic and pharmacodynamic studies, as well as for the development of pediatric formulations. Finding simple ways to inform the world about existing data may save time and facilitate efforts.
Koren
Gideon
G
The Hospital for Sick Children, Ontario, Canada. gkoren@sickkids.ca
Rieder
Michael
M
MacLeod
Stuart M
SM
D002170:Canada; D002648:Child; D002675:Child, Preschool; D004358:Drug Therapy / Q000592:standards / Q000639:trends*; D005060:Europe; D014943:Global Health; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010601:Pharmacology, Clinical / Q000592:standards / Q000639:trends*; D014481:United States